Metabolomics has great potential in the development of new biomarkers in cancer. In this 22 study, metabolomics and gene expression data from breast cancer tumor samples were 23 analyzed, using (1) probabilistic graphical models to define associations using quantitative data 42 predictors of relapse based on the integration of those high-dimensional data in breast 43 cancer patients.
without other a priori information; and (2) Flux Balance Analysis and flux activities to 25 characterize differences in metabolic pathways. A metabolite network was built through the 26 use of probabilistic graphical models. Interestingly, the metabolites were organized into 27 metabolic pathways in this network, thus it was possible to establish differences between 28 breast cancer subtypes at the metabolic pathway level. Additionally, the lipid metabolism node 
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We used two different methods to merge metabolomics and gene expression data in breast 55 cancer. In previous studies, we used probabilistic graphical models (PGMs) to study differences 56 between breast tumor subtypes and to characterize muscle-invasive bladder cancer at a 57 functional level using proteomics data [5] [6] [7] . Flux Balance Analysis (FBA), however, is a method 58 that has been widely used to study biochemical networks [8] . FBA predicts the growth rate or 59 the rate of production of a given metabolite [9] , and it has previously been used to 60 characterize breast cancer cell responses against drugs targeting metabolism [10]. In this 61 study, flux activities were proposed as a feasible method to compare flux patterns in metabolic 62 pathways.
63
In the present study, metabolomics and gene expression data from 67 fresh tissue samples 64 [11] were analyzed through PGMs and FBA. Our aim was to find associations between 65 metabolomics and gene expression data.
66

Results
68
Patient characteristics 69 The data used in this study are from the previous work of Terunuma et al. [11] . A total of 67 70 paired normal and tumor fresh tissue samples from patients with breast cancer were studied.
71
We only selected samples from tumor tissues for the present analyses. (Fig 1) . A 81 multivariate analysis showed that the predictor provided additional prognostic information to 82 that of the clinical data (S1 Table) . 
84
Metabolomics data, including 237 metabolites, were analyzed through PGM. The resulting 85 network was built assigning a main metabolic pathway to each node using IMPaLA. IMPaLA is a 86 tool that allows ontology analyses based on metabolic pathways instead of genes. Strikingly, 87 this network had a functional structure, grouping the metabolites into metabolic pathways.
88
The network had five nodes, each with a different overrepresented metabolic pathway (Fig 2) . 
90
The activity of each node was calculated as previously described [6, 7, 10, 12] . Significant 91 differences were found between ER+ and ER-tumors in lipid metabolism and purine 92 metabolism (p<0.05) (S1 Fig) .
93
The lipid metabolism node had prognostic value in this cohort (p =0.045, HR = 0.479, cut-off = 94 50:50) ( Fig 3) . Differences remained when stratified by the expression of hormonal receptors.
95
However, a multivariate analysis did not show that the predictor supplied additional 96 prognostic information to that of the clinical data (S2 Table) . 
98
Analyses combining gene expression with metabolomics data 99 A network combining metabolomics and gene expression data was built. Although most 100 metabolites were grouped in the same node, some were integrated into gene nodes (Fig 4) . 
103
This combined network was then functionally characterized. The resulting network had eleven 104 functional nodes and a twelfth node that grouped the metabolites (Fig 4) .
105
Once the main functions were assigned, a literature review was performed to study the 106 relationship between metabolites included in the gene nodes and the main function of each 107 node. A relationship with functional nodes had been previously described for 4 of 20 
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A predictor for overall survival was built with flux activities of glutamate metabolism and 119 alanine and aspartate metabolism (p-value = 0.024, HR = 0.411, cut-off = 50:50) ( Fig 5) . A 120 multivariate analysis showed that the predictor provided prognostic information independent 121 from clinical data (S3 Table) . 
129
Division in branches of the network formed by flux activities and metabolomics data.
130
The resulting network was split into several branches to study the relationship of the 131 metabolites to the flux activities included in each branch ( Fig 6) . Coherence between both 132 types of data was shown, associating flux activities and metabolites related to these flux 133 activities in the same branch. For instance, branch 1 includes glycolysis flux activity and three 134 metabolites previously related to glycolysis (S4 Table) . Regarding vitamins and cofactors, it was 135 not possible make comparisons because the IMPaLA label for this category is "Vitamin and co- 
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FBA was used to model metabolism using gene expression data. Although FBA-predicted 187 biomass did not show significant differences between ER+ and ER-tumors, differences in flux 188 activities were shown between both subtypes. Some of these activities were also related to 189 prognosis. One of these flux activities is "Glutamine metabolism", which agrees with the 190 results obtained from the metabolomics data, including glutamine in the metabolite, a 
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Our study has some limitations. The limited number of samples leads us to consider the results 201 as preliminary, and validation in an independent cohort is needed. Additionally, our results are 202 difficult to place in the current clinical landscape, given that tumors in the original series had 203 not been assessed for HER2 expression. On the other hand, evolving techniques currently 204 allow the detection of more metabolites, which would permit a more thorough analysis.
205
In conclusion, PGMs reveal their utility in the analysis of metabolomics data from a functional 206 point of view, not only metabolomics data alone, but also in combination with flux or gene 207 expression data. Therefore, PGM is postulated as a method to propose new hypotheses in the 208 metabolomics field. We also found that it is possible to associate metabolomics data with 209 clinical outcomes and to build prognostic signatures based on metabolomics data.
212
Materials and methods
213
Patients included in the study 214 Metabolomics and gene expression data from 67 fresh tumor tissue samples originally 215 analyzed by Terunuma et al. [11] were included in this study.
216
Preprocessing of gene expression and metabolomics data 217
For the metabolomics data, log2 was calculated. As quality criteria, data were filtered to 218 include detectable measurements in at least 75% of the samples. Missing values were imputed 219 to a normal distribution using Perseus software [23] . After quality control, 237 metabolites 220 were considered for subsequent analyses.
221
In terms of gene expression data, the 2000 most variable genes, i.e., those genes with the 222 highest standard deviation, were chosen to build the PGM.
223
Probabilistic graphical models and gene ontology analyses 224 As previously described [6, 7, 10, 12] 
